骨桥蛋白在人脑胶质瘤中的表达及其临床意义

目的探讨骨桥蛋白在人脑星形胶质细胞瘤中的表达及其临床意义。方法应用免疫组织化学方法检测58例胶质瘤和10例正常脑组织中骨桥蛋白的表达，分析其表达与肿瘤病理分级和预后的关系。结果在正常脑组织中未见骨桥蛋白的表达。Ⅰ-Ⅳ级肿瘤中骨桥蛋白的阳性细胞率分别为11.3％±6．2％、21．8％±11．2％和36．7％±18．3％和49．4％±16．5％，差异有显著性（P〈0．05）。骨桥蛋白高表达和低表达患者2年生存率分别为40．6％（13／32）和76．9％（20／26），差异显著（P〈0．05）。结论骨桥蛋白在胶质瘤的浸润性生长中可能起重要作用，其表达与肿瘤分化程度和患者预后密切相关。

Expression of Osteopontin in Human Brain Gliomas and Its Clinical Meanings

Objective To explore the expression of osteopontin in human gliomas and its clinical meanings. Methods The expression of osteopontin was determined by immunohistochemical stain in 10 cases of normal brain tissues and in 58 cases of gliomas. The relationship of osteopontin expression with pathological grade of gliomas and prognosis of patients with gliomas was analyzed. Results No expression of osteopontin was found in the normal brain tissues. The positive cell rates of osteopontin expression in grades Ⅰ, Ⅱ, Ⅲ and Ⅳ gliomas were 11.3%±6.2%, 21.8%±11.2%, 36.7%±18.3% and 49.4%±16.5% respectively. There was significant difference in osteopontin expression among the gliomas of different pathological grades （P〈0.05）. Two year-survival rates in patients with high and low expressions of osteopontin was 40.6%（13/32） and 76.9%（20/26） respectively. There was significant difference in two year-survive rate beween the patients with high expression of osteopontin and patients with low exptrssion of osteopontin （P〈0.05）. Conclusion Osteopontin may play an important role in the development of human brain gliomas. The expression of osteopontin is associated with pathological grade of gliomas and prognosis in the patients with gliomas.